EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Optipharm.CO.LTD (153710) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Optipharm.CO.LTD KRW 1,148, price KRW 4,575, upside -74.9%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7153710009

OC Thin data Sep 24, 2026

Optipharm.CO.LTD

153710 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,148 KRW · Strongly overvalued (−75%)
!Quality 46/100
!Expensive Growth (revenue 5y +11.4 %/yr)
!Loss-making · -9.3% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Optipharm.CO.LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

17,550 KRW 4,260 KRW Fair Value 1,148 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 4,260 KRW – 17,550 KRW · fair‑value band 856.51 KRW – 1,713 KRW · the 4,575 KRW price screens above the 1,148 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Optipharm.CO.LTD in your weekly email

Every Wednesday you see whether Optipharm.CO.LTD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business.

Show more

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and changed its name to Optipharm.CO.,LTD in 2012. Optipharm.CO.,LTD was founded in 2000 and is based in Cheongju, South Korea.

Stock analysis

Optipharm.CO.LTD (153710) currently trades at 4,575 KRW, while our model-based Fair Value estimate is 1,148 KRW, implying the stock looks roughly 298.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 856.51 KRW (bear) to 1,713 KRW (bull), the price of 4,575 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Optipharm.CO.LTD reported revenue of 22.3B KRW in FY2025 versus 14.3B KRW in FY2021, a compound +11.9%/yr. Reported net income was −2.5B KRW in FY2025.

Key figures

Market cap 67.1B KRW (≈ $49.3M) · P/S ratio 3.04 · Net margin −11.2% · Return on equity −8.3% · Return on assets (EBIT) −7.5% · Operating margin −13.5% · Revenue (TTM) 22.8B KRW · Revenue growth (YoY) +9.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −75%, 153710 screens richer than that median.

Fair Value models

Bear 856.51 KRW Fair Value 1,148 KRW Bull 1,713 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 865.73 KRW 1,160 KRW 1,731 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 865.73 KRW 1,160 KRW 1,731 KRW 54

Open the full fair value analysis →

Notify me when 153710 reaches fair value

Put 153710 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 45 · Market factors (momentum, volatility) 42

Profitability 12
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 61
Balance sheet, leverage, solvency risk
Investment 83
Disciplined investing over empire-building
Low Volatility 76
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 18
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Start year 2020 (pandemic). Over 10 years: +6.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.5% (2020) → −10.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

153710 screens 299% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Optipharm.CO.LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −75% · Bottom 25%
Profitability
Return on assets −3% · Below median
Net margin (TTM) −9% · Below median
Operating margin (TTM) −13% · Below median
Growth and dividend
Revenue growth 9% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)45 · sector 25
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $665.30 $682.58 +3%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Optipharm.CO.LTD · Fair Value
1,148 KRW −299%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Optipharm.CO.LTD Fair Value". https://www.fairvalue-calculator.com/stock/153710

Frequently asked questions

Is Optipharm.CO.LTD (153710) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,148 KRW versus a price of 4,575 KRW, about −75% upside (overvalued).
What is the fair value of 153710?
Our model-based fair value for Optipharm.CO.LTD is 1,148 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,575 KRW.
What is the quality score of 153710?
Optipharm.CO.LTD has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Optipharm.CO.LTD (153710)?
Our model-based price target is the fair value of 1,148 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 856.51 KRW, optimistic scenario 1,713 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Optipharm.CO.LTD stock forecast for 2026?
Our models put fair value at 1,148 KRW, about −75% upside versus a price of 4,575 KRW (overvalued). Cautious scenario 856.51 KRW, optimistic scenario 1,713 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Optipharm.CO.LTD (153710)?
Optipharm.CO.LTD reported trailing-twelve-month revenue of about 22.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Optipharm.CO.LTD (153710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Optipharm.CO.LTD it is 1,148 KRW per share (as of Sep 24, 2026), against a price of 4,575 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Optipharm.CO.LTD stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 153710 trades above its calculated fair value: price 4,575 KRW, fair value 1,148 KRW, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 153710?
No. The price is what the market pays today (4,575 KRW); the fair value is what the company's own numbers justify (1,148 KRW). For Optipharm.CO.LTD the two are 3,427 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Optipharm.CO.LTD worth?
The market values Optipharm.CO.LTD at about 67.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,575 KRW; our models calculate a fair value of 1,148 KRW per share.
What do the bullish and bearish scenarios say about 153710?
Our models span a range for Optipharm.CO.LTD: cautious scenario 856.51 KRW, base 1,148 KRW, optimistic 1,713 KRW per share (as of Sep 24, 2026, price 4,575 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Optipharm.CO.LTD (153710)?
Balance-sheet figures for Optipharm.CO.LTD (as of Sep 24, 2026): return on equity −8.3%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 153710 from its 52-week high?
Optipharm.CO.LTD trades at 4,575 KRW, about 26% below its 52-week high of 6,200 KRW and 7% above the low of 4,260 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,148 KRW is for.
Which stocks are comparable to Optipharm.CO.LTD?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Optipharm.CO.LTD stock attractive at the current price?
The data as of Sep 24, 2026: price 4,575 KRW, calculated fair value 1,148 KRW (−75%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 153710 calculated?
We run Optipharm.CO.LTD through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,148 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Optipharm.CO.LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Optipharm.CO.LTD (153710)?
The closing price on Sep 23, 2026 was 4,575 KRW. Our model-based fair value is 1,148 KRW, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Optipharm.CO.LTD right now?
The price sits above even our optimistic bull case (1,713 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (856.51 KRW to 1,713 KRW) leaves room in how you read the outcome.

Key figures of Optipharm.CO.LTD

How large is the market capitalisation of Optipharm.CO.LTD (153710)?
The market capitalisation of Optipharm.CO.LTD is 67.1B KRW (≈ $49.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Optipharm.CO.LTD (153710)?
The price-to-sales ratio of Optipharm.CO.LTD is 3.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Optipharm.CO.LTD (153710)?
The net margin of Optipharm.CO.LTD is −11.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Optipharm.CO.LTD (153710)?
The return on equity (ROE) of Optipharm.CO.LTD is −8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Optipharm.CO.LTD (153710)?
On an EBIT basis the return on assets of Optipharm.CO.LTD is −7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Optipharm.CO.LTD (153710)?
The operating margin of Optipharm.CO.LTD is −13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Optipharm.CO.LTD (153710)?
Revenue at Optipharm.CO.LTD is growing +9.0% versus a year earlier (3y avg +11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Optipharm.CO.LTD (153710) generate?
The free cash flow of Optipharm.CO.LTD is −4.1B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Optipharm.CO.LTD (153710) carry?
The net debt of Optipharm.CO.LTD is 8.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Optipharm.CO.LTD in the live analysis

One click puts Optipharm.CO.LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.